



PB 145 of 2024

National Health (Minimum Stockholding) Amendment Determination (No. 12) 2024

I, Eden Simon, as delegate of the Minister for Health and Aged Care, make the following determination.

Dated 20 December 2024

Eden Simon
Acting Assistant Secretary
Pricing and PBS Policy Branch
Technology Assessment and Access Division
Department of Health and Aged Care

Contents

1 Name	1
2 Commencement.....	1
3 Authority	1
4 Schedules.....	1
Schedule 1—Amendments commencing 1 January 2025	2
<i>National Health (Minimum Stockholding) Determination 2023</i>	2
Schedule 2—Amendments commencing 1 April 2025	9
<i>National Health (Minimum Stockholding) Determination 2023</i>	9
Schedule 3—Amendments commencing immediately after the commencement of Schedule 2 to the <i>National Health (Minimum Stockholding) Amendment Determination (No. 10) 2024 – 1 April 2025</i>	12
<i>National Health (Minimum Stockholding) Determination 2023</i>	12
Schedule 4—Amendments commencing 1 June 2025	13
<i>National Health (Minimum Stockholding) Determination 2023</i>	13

1 Name

- (1) This instrument is the *National Health (Minimum Stockholding) Amendment Determination (No. 12) 2024*.
- (2) This instrument may also be cited as PB 145 of 2024.

2 Commencement

- (1) Each provision of this instrument specified in column 1 of the table commences, or is taken to have commenced, in accordance with column 2 of the table. Any other statement in column 2 has effect according to its terms.

Commencement information		
Column 1	Column 2	Column 3
Provisions	Commencement	Date/Details
1. Sections 1 to 4 and anything in this instrument not elsewhere covered by this table	1 January 2025.	1 January 2025
2. Schedule 1	1 January 2025.	1 January 2025
3. Schedule 2	1 April 2025.	1 April 2025
4. Schedule 3	Immediately after the commencement of Schedule 2 to the <i>National Health (Minimum Stockholding) Amendment Determination (No. 10) 2024</i> .	1 April 2025
4. Schedule 4	1 June 2025.	1 June 2025

- (2) Any information in column 3 of the table is not part of this instrument. Information may be inserted in this column, or information in it may be edited, in any published version of this instrument.

3 Authority

This instrument is made under subsection 99AEKC(2) of the *National Health Act 1953*.

4 Schedules

Each instrument that is specified in a Schedule to this instrument is amended or repealed as set out in the applicable items in the Schedule concerned, and any other item in a Schedule to this instrument has effect according to its terms.

Schedule 1—Amendments commencing 1 January 2025

National Health (Minimum Stockholding) Determination 2023

1 Schedule 1 (table)

	Omit:				
Atenolol	Oral solution 50 mg in 10 mL, 300 mL	Oral	Atenolol-AFT	4 months stock by reference to usual PBS demand	
	substitute:				
Atenolol	Oral solution 50 mg in 10 ml, 300 ml	Oral	Atenolol-AFT	(a) between 1 January 2025 and 31 May 2025—4 months stock by reference to usual PBS demand (b) after 31 May 2025—6 months stock by reference to usual PBS demand	

2 Schedule 1 (table)

	Omit:				
Bisoprolol	Tablet containing bisoprolol fumarate 10 mg	Oral	Cipla Bisoprolol	between 1 July 2024 and 31 December 2024—0 months stock by reference to usual demand	
Bisoprolol	Tablet containing bisoprolol fumarate 2.5 mg	Oral	Cipla Bisoprolol	between 1 July 2024 and 31 December 2024—0 months stock by reference to usual demand	
Bisoprolol	Tablet containing bisoprolol fumarate 5 mg	Oral	Cipla Bisoprolol	between 1 July 2024 and 31 December 2024—0 months stock by reference to usual demand	

3 Schedule 1 (table)

	Omit:				
Cefazolin	Powder for injection 1 g (as sodium)	Injection	Cefazolin-AFT	between 1 December 2024 and 31 May 2025—4 months stock by reference to usual demand	
	substitute:				
Cefazolin	Powder for injection 1 g (as sodium)	Injection	Cefazolin-AFT	300,000 packs of a pack quantity of 5	

4 Schedule 1 (table)

Omit:

Celecoxib	Capsule 100 mg	Oral	NOUMED CELECOXIB	between 1 November 2024 and 31 December 2024— 0 months stock by reference to usual demand
Celecoxib	Capsule 200 mg	Oral	NOUMED CELECOXIB	between 1 November 2024 and 31 December 2024— 0 months stock by reference to usual demand

5 Schedule 1 (table)

Omit:

Duloxetine	Capsule 30 mg (as hydrochloride)	Oral	Cymbalta	between 1 November 2024 and 31 December 2024— 0 months stock by reference to usual demand
Duloxetine	Capsule 60 mg (as hydrochloride)	Oral	Cymbalta	between 1 November 2024 and 31 December 2024— 0 months stock by reference to usual demand

6 Schedule 1 (table)

Omit:

Fluoxetine	Capsule 20 mg (as hydrochloride)	Oral	Prozac 20	between 1 November 2024 and 31 December 2024— 0 months stock by reference to usual demand
------------	-------------------------------------	------	-----------	--

7 Schedule 1 (table)

Omit:

Hypromellose	Eye drops 3 mg per mL, 10 mL	Application to the Eye	Gentel	between 1 July 2024 and 31 December 2024—0 months stock by reference to usual demand
Hypromellose	Eye drops 3 mg per mL, 10 mL	Application to the Eye	In a Wink Moisturising	between 1 July 2024 and 31 December 2024—0 months stock by reference to usual demand

8 Schedule 1 (table)

Omit:

Lamotrigine	Tablet 100 mg	Oral	NOUMED LAMOTRIGINE	between 1 November 2024 and 31 December 2024— 0 months stock by reference to usual demand
Lamotrigine	Tablet 200 mg	Oral	NOUMED LAMOTRIGINE	between 1 November 2024 and 31 December 2024— 0 months stock by reference to usual demand
Lamotrigine	Tablet 25 mg	Oral	NOUMED LAMOTRIGINE	between 1 November 2024 and 31 December 2024— 0 months stock by reference to usual demand
Lamotrigine	Tablet 50 mg	Oral	NOUMED LAMOTRIGINE	between 1 November 2024 and 31 December 2024— 0 months stock by reference to usual demand
Lansoprazole	Capsule 30 mg	Oral	NOUMED LANSOPRAZOLE	between 1 November 2024 and 31 December 2024— 0 months stock by reference to usual demand

9 Schedule 1 (table item dealing with the drug Methoxyflurane, column number 4)

Omit “Penthrox”, substitute “Penthrox (Combination Pack)”.

10 Schedule 1 (table)

Omit:

Nortriptyline	Tablet 10 mg (as hydrochloride)	Oral	NortriTABS 10 mg	between 1 October 2024 and 31 December 2024— 0 months stock by reference to usual demand
Nortriptyline	Tablet 25 mg (as hydrochloride)	Oral	NortriTABS 25 mg	between 1 October 2024 and 31 December 2024— 0 months stock by reference to usual demand

11 Schedule 1 (table)

Omit:

Phenoxyethylpenicillin	Powder for oral liquid 125 mg (as potassium) per 5 mL, 100 mL	Oral	Phenoxyethylpenicillin-AFT	between 1 December 2024 and 31 May 2025—4 months stock by reference to usual demand
------------------------	---	------	----------------------------	---

12 Schedule 1 (table)

Omit:

Pregabalin	Capsule 150 mg	Oral	NOUMED PREGABALIN	between 1 November 2024 and 31 December 2024—0 months stock by reference to usual demand
Pregabalin	Capsule 25 mg	Oral	NOUMED PREGABALIN	between 1 November 2024 and 31 December 2024—0 months stock by reference to usual demand
Pregabalin	Capsule 300 mg	Oral	NOUMED PREGABALIN	between 1 November 2024 and 31 December 2024—0 months stock by reference to usual demand
Pregabalin	Capsule 75 mg	Oral	NOUMED PREGABALIN	between 1 November 2024 and 31 December 2024—0 months stock by reference to usual demand

13 Schedule 1 (table)

Omit:

Ramipril	Tablet 1.25 mg	Oral	Tryzan Tabs 1.25	(a) between 1 July 2023 and 31 December 2023—1 month stock by reference to usual demand (b) after 31 December 2023—3 months stock by reference to usual demand
Ramipril	substitute: Tablet 1.25 mg	Oral	Ramipril Viatris	(a) between 1 January 2025 and

28 February 2025—3 months stock by reference to usual demand of Tryzan Tabs 1.25
 (b) after 28 February 2025—3 months stock by reference to usual demand of both Ramipril Viatris and Tryzan Tabs 1.25 added together

14 Schedule 1 (table)

	After:				
Ramipril	Tablet 1.25 mg	Oral	Ramipril Viatris	(a) between 1 January 2025 and 28 February 2025—3 months stock by reference to usual demand of Tryzan Tabs 1.25 (b) after 28 February 2025—3 months stock by reference to usual demand of both Ramipril Viatris and Tryzan Tabs 1.25 added together	
	insert:				
Ramipril	Tablet 10 mg	Oral	Ramipril Viatris	after 28 February 2025—6 months stock by reference to usual demand of both Ramipril Viatris and Tryzan Tabs 10 added together	
Ramipril	Tablet 2.5 mg	Oral	Ramipril Viatris	after 28 February 2025—6 months stock by reference to usual demand of both Ramipril Viatris and Tryzan Tabs 2.5 added together	
Ramipril	Tablet 5 mg	Oral	Ramipril Viatris	after 28 February 2025—6 months stock by reference to usual demand of both Ramipril Viatris and	

Tryzan Tabs 5 added together

15 Schedule 1 (table)

Omit:

Sertraline	Tablet 100 mg (as hydrochloride)	Oral	NOUMED SERTRALINE	between 1 November 2024 and 31 December 2024— 0 months stock by reference to usual demand
Sertraline	Tablet 50 mg (as hydrochloride)	Oral	NOUMED SERTRALINE	between 1 November 2024 and 31 December 2024— 0 months stock by reference to usual demand

16 Schedule 1 (table)

Omit:

Simvastatin	Tablet 10 mg	Oral	NOUMED SIMVASTATIN	between 1 November 2024 and 31 December 2024— 0 months stock by reference to usual demand
Simvastatin	Tablet 20 mg	Oral	NOUMED SIMVASTATIN	between 1 November 2024 and 31 December 2024— 0 months stock by reference to usual demand
Simvastatin	Tablet 40 mg	Oral	NOUMED SIMVASTATIN	between 1 November 2024 and 31 December 2024— 0 months stock by reference to usual demand

17 Schedule 1 (table)

Omit:

Telmisartan	Tablet 80 mg	Oral	NOUMED TELMISARTAN	between 1 November 2024 and 31 December 2024— 0 months stock by reference to usual demand
-------------	--------------	------	-----------------------	--

18 Schedule 1 (table)

After:

Tenofovir	Tablet containing tenofovir disoproxil fumarate 300 mg	Oral	Tenofovir ARX	4 months stock by reference to usual demand of both
-----------	--	------	---------------	---

Tenofovir	insert: Tablet containing tenofovir disoproxil fumarate 300 mg	Oral	Viread	Tenofovir APOTEX and Tenofovir ARX added together between 1 January 2025 and 31 March 2025—2 months stock by reference to usual demand
-----------	---	------	--------	---

Schedule 2—Amendments commencing 1 April 2025

National Health (Minimum Stockholding) Determination 2023

1 Schedule 1 (table)

Omit:				
Abacavir with lamivudine	Tablet containing abacavir 600 mg (as sulfate) with lamivudine 300 mg	Oral	Abacavir/Lamivudine Viartis	after 31 December 2024—4 months stock by reference to usual demand of both Abacavir/Lamivudine Viartis and Abacavir/Lamivudine Mylan added together
Acamprosate	Tablet (enteric coated) containing acamprosate calcium 333 mg	Oral	Acamprosate Viartis	after 30 July 2024—4 months stock by reference to usual demand of both Acamprosate Viartis and Acamprosate Mylan added together

2 Schedule 1 (table)

Omit:				
Ceftriaxone	Powder for injection 1 g (as sodium)	Injection	Ceftriaxone Viartis	after 31 May 2024—6 months stock by reference to usual demand of both Ceftriaxone Viartis and Ceftriaxone Alphapharm added together
substitute:				
Ceftriaxone	Powder for injection 1 g (as sodium)	Injection	Ceftriaxone Viartis	6 months stock by reference to usual demand

3 Schedule 1 (table)

Omit:				
Dosulepin	Capsule containing dosulepin hydrochloride 25 mg	Oral	Dosulepin Viartis	after 31 May 2024—6 months stock by reference to usual demand of both Dosulepin Viartis and Dosulepin Mylan added together
substitute:				
Dosulepin	Capsule containing dosulepin hydrochloride 25 mg	Oral	Dosulepin Viartis	6 months stock by reference to usual demand

4 Schedule 1 (table)

Omit:

Entecavir	Tablet 0.5 mg (as monohydrate)	Oral	Entecavir Viatris	after 30 September 2024—4 months stock by reference to usual demand of both Entecavir Viatris and Entecavir Mylan added together
-----------	--------------------------------	------	-------------------	--

5 Schedule 1 (table)

Omit:

Esomeprazole	Tablet (enteric coated) 20 mg (as magnesium trihydrate)	Oral	Esomeprazole Viatris	after 31 December 2024—4 months stock by reference to usual demand of both Esomeprazole Viatris and Esomeprazole Mylan added together
--------------	---	------	----------------------	---

Esomeprazole	Tablet (enteric coated) 40 mg (as magnesium trihydrate)	Oral	Esomeprazole Viatris	after 31 December 2024—4 months stock by reference to usual demand of both Esomeprazole Viatris and Esomeprazole Mylan added together
--------------	---	------	----------------------	---

6 Schedule 1 (table)

Omit:

Nevirapine	Tablet 200 mg	Oral	Nevirapine Viatris	after 30 November 2024—4 months stock by reference to usual demand of both Nevirapine Viatris and Nevirapine Alphapharm added together
------------	---------------	------	--------------------	--

7 Schedule 1 (table)

Omit:

Oxycodone	Tablet containing oxycodone hydrochloride 5 mg	Oral	Oxycodone Viatris	after 28 February 2024—6 months stock by reference to usual demand of both Oxycodone Viatris and Oxycodone Mylan added together
-----------	--	------	-------------------	---

substitute:

Oxycodone	Tablet containing oxycodone hydrochloride 5 mg	Oral	Oxycodone Viatris	6 months stock by reference to usual demand
-----------	--	------	-------------------	---

8 Schedule 1 (table)

Omit:

Tenofovir with emtricitabine	Tablet containing tenofovir disoproxil maleate 300 mg with emtricitabine 200 mg	Oral	Tenofovir Disoproxil Emtricitabine Viatris 300/200	after 30 April 2024—4 months stock by reference to usual demand of both Tenofovir Disoproxil Emtricitabine Viatris 300/200 and Tenofovir Disoproxil Emtricitabine Mylan 300/200 added together
------------------------------	---	------	--	--

9 Schedule 1 (table)

Omit:

Tobramycin	Injection 80 mg in 2 mL	Injection	Tobramycin Viatris	4 months stock by reference to usual demand of both Tobramycin Viatris and Tobramycin Mylan added together
------------	-------------------------	-----------	--------------------	--

10 Schedule 1 (table)

Omit:

Trimethoprim	Tablet 300 mg	Oral	Trimethoprim Viatris	after 30 April 2024—6 months stock by reference to usual demand of both Trimethoprim Viatris and Trimethoprim Mylan added together
--------------	---------------	------	----------------------	--

substitute:

Trimethoprim	Tablet 300 mg	Oral	Trimethoprim Viatris	6 months stock by reference to usual demand
--------------	---------------	------	----------------------	---

**Schedule 3—Amendments commencing immediately after
the commencement of Schedule 2 to the *National
Health (Minimum Stockholding) Amendment
Determination (No. 10) 2024 – 1 April 2025***

National Health (Minimum Stockholding) Determination 2023

1 Schedule 1 (table)

	Omit:				
Atropine	Injection containing atropine sulfate monohydrate 600 micrograms in 1 mL	Injection	Atropine Injection (Pfizer)		6 months stock by reference to usual PBS demand
	substitute:				
Atropine	Injection containing atropine sulfate monohydrate 600 micrograms in 1 mL	Injection	Atropine Injection (Bridgewest)	(a) between 1 April 2025 and 30 September 2025—6 months stock by reference to usual PBS demand of Atropine Injection (Pfizer)	
				(b) between 1 October 2025 and 31 March 2026—6 months stock by reference to usual PBS demand of both Atropine Injection (Pfizer) and Atropine Injection (Bridgewest) added together	
				(c) after 31 March 2026—6 months stock by reference to usual PBS demand	

Schedule 4—Amendments commencing 1 June 2025

National Health (Minimum Stockholding) Determination 2023

1 Schedule 1 (table)

	After:			
Escitalopram	Tablet 20 mg (as oxalate)	Oral	APX-Escitalopram	4 months stock by reference to usual demand
	insert:			
Estradiol and estradiol with norethisterone	Pack containing 4 transdermal patches 780 micrograms estradiol (as hemihydrate) and 4 transdermal patches 620 micrograms estradiol (as hemihydrate) with 2.7 mg norethisterone acetate	Transdermal	Estalis sequi 50/140	6 months stock by reference to usual PBS demand
Estradiol with norethisterone	Transdermal patches containing 620 micrograms estradiol (as hemihydrate) with 2.7 mg norethisterone acetate, 8	Transdermal	Estalis continuous 50/140	6 months stock by reference to usual PBS demand